TotalMarketCap

Lyell Immunopharma

LYELNasdaq United StatesHealth CareBiotechnology: Pharmaceutical Preparations

Market cap

$360.916 M

$14.68 -4.86%

Close of 6 Nov 2026

As of 6 Nov 2026, Lyell Immunopharma (LYEL) has a market capitalization of $360.9M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$36.0K

#3594 by revenue

Earnings

-$274.4M

Loss-making

Shares outstanding

24,585,565

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →
  1. #208BlossomHill TherapeuticsBLSM$385.2M
  2. #209AltimmuneALT$382.2M
  3. #210Lyell ImmunopharmaLYEL$360.9M
  4. #211Avalo TherapeuticsAVTX$355.6M
  5. #212RezoluteRZLT$354.5M

What if Lyell Immunopharma were worth as much as…

Open the what-if tool →

Gold $28.2T

$1,148,514

Per share 78,237× higher

Bitcoin $1.53T

$62,144.11

Per share 4,233× higher

Apple $5.02T

$204,013.32

Per share 13,897× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Lyell Immunopharma are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.